Why Acadia Pharmaceuticals (ACAD) Stock Rose 10.8% on Nov 10, 2026
as of Tuesday, 4:48 PM ET
The reason we found
Revenue Beat and Guidance Lift Acadia Shares
Acadia reported third-quarter revenue of $342.3 million, highlighted stronger Daybue and Nuplazid sales, and issued full-year revenue guidance of $1.26 billion to $1.3 billion. Those operating updates plausibly drove the sharp gain, although reduced research-and-development guidance and ongoing pipeline concerns make the catalyst somewhat mixed.
earnings and guidancemedium confidence
Sources 7
- What Has The Market Missed In Acadia Pharmaceuticals Stock’s Drop? - Trefisnews.google.com
- Acadia Pharmaceuticals Fell While Sales Rosefinance.yahoo.com
- Acadia Pharmaceuticals Fell While Sales Rosefinnhub.io
- Acadia Pharmaceuticals Comments on Federal Circuit Oral Argument in NUPLAZID® Formulation Patent Appealfinnhub.io
- Acadia Pharmaceuticals (ACAD) Stock Still Looks Like A Bargain Todayfinnhub.io
- Acadia Pharmaceuticals (ACAD) Cuts 2026 R And D Guidance, Is It Still 46% Undervalued?finnhub.io
- Acadia Pharmaceuticals to Present Remlifanserin Data at the 2026 Clinical Trials on Alzheimer's Disease (CTAD) Conferencefinnhub.io
Our call
Sell somedated Nov 10, 2026
Acadia Pharmaceuticals fell 14% over the past five trading days after its Nov 4 report beat profit forecasts by 63%, and two fewer analysts rate it a buy than three months ago. We'd stop selling if Acadia Pharmaceuticals' next report beats profit forecasts.
Other moves on Nov 10
- HIMS−16.5%Earnings miss and weaker outlook trigger Hims & Hers selloff
- LFVN−13.6%LifeVantage Stock Falls After Revenue Drops 22%
- QLYS−13.3%Qualys Falls Despite Earnings Beat on Tepid Revenue Outlook
- ASTS−8.7%AST SpaceMobile slides after earnings miss and price-target cut
- BDSX−8.5%Analyst trims Biodesix target despite maintaining Buy rating
- SERV−8.4%Analyst lowers Serve Robotics price target, pressuring shares